Polysaccharide-Based Chiral Chromatography Media in HPLC and SFC - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Polysaccharide-Based Chiral Chromatography Media in HPLC and SFC
Polysaccharide-based chiral stationary phases have been developed that comprise chiral selectors immobilized on their support rather than being physically coated. These materials are completely solvent stable, thereby increasing selectivity and and enabling the development of new chiral selectors that have been too unstable in a coated form for general use.

Pharmaceutical Technology

Although the first enantiomeric separations were carried out during the early past century, it was not until 1973 that the first generally useful chiral stationary phase (CSP), cellulose triacetate, was developed. This phase was used primarily for preparative separations until the work of Professor Pirkle in the United States and Professor Okamoto in Japan made analytical CSPs readily available. Although the Pirkle phases provided good separations, the polysaccharide-based CSPs developed by Okamoto had very wide applicability.

It was subsequently found that the majority of enantiomeric separations could be achieved using just four different derivatives—two based on cellulose and two based on amylose. These polysaccharide phases were prepared by first derivatizing native amylose or cellulose and then coating these chiral polymers on a silica-gel base. This preparation method led to phase instability to certain organic solvents in which the polymers are partially or fully soluble.

Many methods have been developed to allow the immobilization or chemical bonding of the polysaccharide-based polymers to the silica support (1). Methods include cross-linking the polymer by use of diisocyanates (2), unsaturated groups that are subsequently polymerized (3, 4), silyl derivatives (5), direct bonding of the polysaccharide to silica by enzymatic or chemical routes before derivatization (6), and cross-linking of the chiral polymer by photochemical or free-radical reactions (7). All of these methods produce somewhat different products with different chromatographic properties.

Immobilization of the chiral polymer to the silica support has several benefits. The CSP is not destroyed on contact with a solvent that swells or dissolves (even partially) the polymer. The sensitivity of the first-generation CSPs to even small concentrations of such solvents often required the use of dedicated equipment to eliminate all chances of accidental introduction of a "forbidden" solvent.

Immobilization of the chiral polymer thus brings a new generation of polysaccharide-based CSPs into line with the stability of other high-performance liquid chromatography (HPLC) phases (such as C18 and CN), which means a significant extension of the column lifetime and the elimination of sudden column failure because of an accident. Others benefits of the immobilization process are that otherwise difficult separations can be achieved by using solvents that previously could not be used with the coated phases and that new selectivity can be developed by using previously unusable chiral selectors.

Immobilized CSP

Figure 1: Structures of the immobilized chiral stationary phases.
The 3,5-dimethylphenylcarbamates of amylose and cellulose are the most useful polysaccharide-based CSPs. They are commercialized as "Chiralpak IA" and "Chiralpak IB," respectively (Daicel Chemical Industries, Osaka, Japan) (see Figure 1). Other polysaccharide-based chiral selectors include the 3,5-dichlorophenylcarbamate of cellulose, which was first introduced by Okamoto as a coated CSP. Although it had limited utility because of its solubility in hexane-based mobile phases, it demonstrated sufficiently interesting selectivity when used with pure alcohol mobile phases to be of interest as an immobilized phase. Daicel introduced a CSP of similar structure, immobilized by a proprietary technology, as "Chiralpak IC" (see Figure 1).

Selectivity and separations


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here